Search results
Showing 766 to 780 of 7679 results
Cemiplimab for treating recurrent or metastatic cervical cancer (terminated appraisal) (TA901)
NICE is unable to make a recommendation on cemiplimab (Libtayo) for treating recurrent or metastatic cervical cancer in adults because Sanofi did not provide an evidence submission. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA901
NICE is unable to make a recommendation on ciltacabtagene autoleucel (Carvykti) for treating relapsed or refractory multiple myeloma in adults. This is because Janssen withdrew its evidence submission for the appraisal. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA889
NICE is unable to recommend the use in the NHS of methylnaltrexone for treating opioid-induced bowel dysfunction in people with advanced illness...
Show all sections
Sections for TA277
NICE is unable to make a recommendation on capmatinib (Tabrecta) for treating advanced non-small-cell lung cancer with MET exon 14 skipping in adults. This is because Novartis Pharmaceuticals did not provide an evidence submission. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA884
NICE is unable to make a recommendation about the use in the NHS of carmustine implants because no evidence submission was received from the
Show all sections
Sections for TA149
NICE is unable to make a recommendation on decitabine–cedazuridine (Inaqovi) for untreated acute myeloid leukaemia in adults when intensive chemotherapy is unsuitable. This is because Otsuka Pharmaceuticals (UK) did not provide an evidence submission. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA932
NICE is unable to make a recommendation on tisagenlecleucel (Kymriah) for treating relapsed or refractory diffuse large B-cell lymphoma in adults after 2 or more systemic therapies. This is because Novartis did not provide a complete evidence submission.
Show all sections
Sections for TA933
NICE is unable to make a recommendation on idecabtagene vicleucel (Abecma) for treating relapsed and refractory multiple myeloma after 3 or more treatments in adults. This is because BMS did not provide an evidence submission. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA936
Ravulizumab for treating generalised myasthenia gravis (terminated appraisal) (TA940)
NICE is unable to make a recommendation on ravulizumab (Ultomiris) for treating generalised myasthenia gravis in adults. This is because Alexion Pharma UK withdrew its evidence submission. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA940
NICE is unable to make a recommendation on ravulizumab (Ultomiris) for treating AQP4 antibody-positive neuromyelitis optica spectrum disorder in adults. This is because Alexion Pharma UK withdrew its evidence submission. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA941
Bevacizumab for the treatment of non-small-cell lung cancer (terminated appraisal) (TA148)
NICE is unable to recommend the use in the NHS of bevacizumab in addition to platinum-based chemotherapy for the first-line treatment of patients with unresectable advanced, metastatic or recurrent non-small-cell lung cancer (other than predominantly squamous cell histology) because no evidence submission was received from the manufacturer or sponsor of the technology.
Show all sections
Sections for TA148
NICE is unable to make a recommendation on dupilumab (Dupixent) for treating eosinophilic oesophagitis in people 12 years and over. This is because Sanofi did not provide an evidence submission. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA938
Patisiran for treating hereditary transthyretin amyloidosis (HST10)
Evidence-based recommendations on patisiran (Onpattro) for treating hereditary transthyretin amyloidosis in adults with stage 1 and stage 2 polyneuropathy.
Evidence-based recommendations on voretigene neparvovec (Luxturna) for RPE65-mediated inherited retinal dystrophies in people with vision loss caused by inherited retinal dystrophy from confirmed biallelic RPE65 mutations and who have sufficient viable retinal cells.
Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (HST12)
Evidence-based recommendations on cerliponase alfa (Brineura) for treating neuronal ceroid lipofuscinosis type 2 in children.